Edmond DE Rothschild Holding S.A. Sells 37,659 Shares of CVS Health Co. (NYSE:CVS)

Edmond DE Rothschild Holding S.A. reduced its position in shares of CVS Health Co. (NYSE:CVS) by 3.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,132,024 shares of the pharmacy operator’s stock after selling 37,659 shares during the period. CVS Health comprises about 0.9% of Edmond DE Rothschild Holding S.A.’s investment portfolio, making the stock its 26th biggest position. Edmond DE Rothschild Holding S.A.’s holdings in CVS Health were worth $50,817,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC boosted its holdings in shares of CVS Health by 28.7% in the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock worth $2,951,000 after acquiring an additional 10,465 shares in the last quarter. Principal Financial Group Inc. boosted its stake in CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after purchasing an additional 66,244 shares in the last quarter. Hall Laurie J Trustee grew its holdings in shares of CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock worth $517,000 after purchasing an additional 11,468 shares during the last quarter. B&D White Capital Company LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at $417,000. Finally, TOMS Capital Investment Management LP bought a new position in shares of CVS Health in the third quarter valued at about $121,987,000. 80.66% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CVS has been the subject of several research reports. Piper Sandler raised their price objective on shares of CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a research report on Friday, March 21st. Barclays boosted their price objective on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Leerink Partnrs upgraded CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. Finally, Evercore ISI raised their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $70.39.

Insider Activity

In other news, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. This represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.

CVS Health Price Performance

Shares of CVS stock opened at $67.13 on Monday. The firm has a market capitalization of $84.64 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $79.98. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The firm has a fifty day moving average of $62.12 and a 200-day moving average of $57.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health’s payout ratio is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.